Beta-amyloid imaging in dementia
Alzheimer's disease (AD) is a neurodegenerative disorder associated with extracellular plaques, composed of amyloid-beta (Aβ), in the brain. Although the precise mechanism underlying the neurotoxicity of Aβ has not been established, Aβ accumulation is the primary event in a cascade of events th...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Yeungnam University College of Medicine
2018-06-01
|
Series: | Yeungnam University Journal of Medicine |
Subjects: | |
Online Access: | http://yujm.yu.ac.kr/upload/pdf/yujm-35-1.pdf |
id |
doaj-afa35d6e78324653becbfcb8cb2ccb9c |
---|---|
record_format |
Article |
spelling |
doaj-afa35d6e78324653becbfcb8cb2ccb9c2020-11-24T21:16:08ZengYeungnam University College of MedicineYeungnam University Journal of Medicine2384-02932018-06-013511610.12701/yujm.2018.35.1.11905Beta-amyloid imaging in dementiaKyung Ah ChunAlzheimer's disease (AD) is a neurodegenerative disorder associated with extracellular plaques, composed of amyloid-beta (Aβ), in the brain. Although the precise mechanism underlying the neurotoxicity of Aβ has not been established, Aβ accumulation is the primary event in a cascade of events that lead to neurofibrillary degeneration and dementia. In particular, the Aβ burden, as assessed by neuroimaging, has proved to be an excellent predictive biomarker. Positron emission tomography, using ligands such as 11C-labeled Pittsburgh Compound B or 18F-labeled tracers, such as 18F-florbetaben, 18F-florbetapir, and 18F-flutemetamol, which bind to Aβ deposits in the brain, has been a valuable technique for visualizing and quantifying the deposition of Aβ throughout the brain in living subjects. Aβ imaging has very high sensitivity for detecting AD pathology. In addition, it can predict the progression from mild cognitive impairment to AD, and contribute to the development of disease-specific therapies.http://yujm.yu.ac.kr/upload/pdf/yujm-35-1.pdfAlzheimer’s diseaseAmyloid-betaPositron emission tomography |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kyung Ah Chun |
spellingShingle |
Kyung Ah Chun Beta-amyloid imaging in dementia Yeungnam University Journal of Medicine Alzheimer’s disease Amyloid-beta Positron emission tomography |
author_facet |
Kyung Ah Chun |
author_sort |
Kyung Ah Chun |
title |
Beta-amyloid imaging in dementia |
title_short |
Beta-amyloid imaging in dementia |
title_full |
Beta-amyloid imaging in dementia |
title_fullStr |
Beta-amyloid imaging in dementia |
title_full_unstemmed |
Beta-amyloid imaging in dementia |
title_sort |
beta-amyloid imaging in dementia |
publisher |
Yeungnam University College of Medicine |
series |
Yeungnam University Journal of Medicine |
issn |
2384-0293 |
publishDate |
2018-06-01 |
description |
Alzheimer's disease (AD) is a neurodegenerative disorder associated with extracellular plaques, composed of amyloid-beta (Aβ), in the brain. Although the precise mechanism underlying the neurotoxicity of Aβ has not been established, Aβ accumulation is the primary event in a cascade of events that lead to neurofibrillary degeneration and dementia. In particular, the Aβ burden, as assessed by neuroimaging, has proved to be an excellent predictive biomarker. Positron emission tomography, using ligands such as 11C-labeled Pittsburgh Compound B or 18F-labeled tracers, such as 18F-florbetaben, 18F-florbetapir, and 18F-flutemetamol, which bind to Aβ deposits in the brain, has been a valuable technique for visualizing and quantifying the deposition of Aβ throughout the brain in living subjects. Aβ imaging has very high sensitivity for detecting AD pathology. In addition, it can predict the progression from mild cognitive impairment to AD, and contribute to the development of disease-specific therapies. |
topic |
Alzheimer’s disease Amyloid-beta Positron emission tomography |
url |
http://yujm.yu.ac.kr/upload/pdf/yujm-35-1.pdf |
work_keys_str_mv |
AT kyungahchun betaamyloidimagingindementia |
_version_ |
1726016979293175808 |